Your browser doesn't support javascript.
loading
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Janjigian, Yelena Y; Kawazoe, Akihito; Bai, Yuxian; Xu, Jianming; Lonardi, Sara; Metges, Jean Phillipe; Yanez, Patricio; Wyrwicz, Lucjan S; Shen, Lin; Ostapenko, Yuriy; Bilici, Mehmet; Chung, Hyun Cheol; Shitara, Kohei; Qin, Shu-Kui; Van Cutsem, Eric; Tabernero, Josep; Li, Kan; Shih, Chie-Schin; Bhagia, Pooja; Rha, Sun Young.
Afiliación
  • Janjigian YY; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: janjigiy@mskcc.org.
  • Kawazoe A; National Cancer Hospital East, Kashiwa, Japan.
  • Bai Y; Harbin Medical University Cancer Hospital, Harbin, China.
  • Xu J; The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Lonardi S; Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Metges JP; CHU Brest-Institut de Cancerologie et d'Hematologie ARPEGO Network, Brest, France.
  • Yanez P; Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile.
  • Wyrwicz LS; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
  • Shen L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Ostapenko Y; National Cancer Institute Ukraine, Kyiv, Ukraine.
  • Bilici M; Atatürk University Faculty of Medicine, Erzurum, Türkiye.
  • Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Shitara K; National Cancer Hospital East, Kashiwa, Japan.
  • Qin SK; Nanjing Tianyinshan Hospital of China Pharmaceutical University, Nanjing, China.
  • Van Cutsem E; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium.
  • Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, Uvic-UCC, Barcelona, Spain.
  • Li K; Merck & Co, Rahway, NJ, USA.
  • Shih CS; Merck & Co, Rahway, NJ, USA.
  • Bhagia P; Merck & Co, Rahway, NJ, USA.
  • Rha SY; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Lancet ; 402(10418): 2197-2208, 2023 12 09.
Article en En | MEDLINE | ID: mdl-37871604
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 3_ND / 4_TD / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles / 3_diarrhea / 4_diarrhoeal_infections / 6_digestive_diseases / 6_esophagus_cancer / 6_stomach_cancer Asunto principal: Neoplasias Esofágicas / Adenocarcinoma Límite: Female / Humans / Male Idioma: En Revista: Lancet Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 3_ND / 4_TD / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles / 3_diarrhea / 4_diarrhoeal_infections / 6_digestive_diseases / 6_esophagus_cancer / 6_stomach_cancer Asunto principal: Neoplasias Esofágicas / Adenocarcinoma Límite: Female / Humans / Male Idioma: En Revista: Lancet Año: 2023 Tipo del documento: Article